triflusal

Also known as SID11112328, Aflen

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid (ASA; Aspirin) in which a hydrogen atom on the benzene ring has been replaced by a trifluoromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux.

In the Vinony graph

Vinony's link graph records 313 inbound references to triflusal, and connects out to aspirin, hirudin and coagulation factor X.

Vinony files it under Acetylsalicylic acids, Antiplatelet drugs and Drugs with no legal status.

Vinony links it to 12 Wikipedia language editions.

Key facts

Drug.IUPAC_name: 2-acetyloxy-4-(trifluoromethyl)benzoic acid
Drug.image: Triflusal2DCSD.svg
Drug.image_class: skin-invert-image
Drug.CAS_number: 322-79-2
Drug.ATC_prefix: B01
Drug.ATC_suffix: AC18
Drug.PubChem: 9458
Drug.DrugBank: DB08814
Drug.UNII: 1Z0YFI05OO
Drug.ChEMBL: 1332032
Drug.ChemSpiderID: 9086
Drug.C: 10
Drug.H: 7
Drug.F: 3
Drug.O: 4
Drug.smiles: CC(=O)Oc1cc(ccc1C(=O)O)C(F)(F)F
Drug.StdInChI: 1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
Drug.StdInChIKey: RMWVZGDJPAKBDE-UHFFFAOYSA-N

via Wikipedia infobox

Chemical data

Formula: C10H7F3O4
Molecular weight: 248.15 g/mol
IUPAC name: 2-acetyloxy-4-(trifluoromethyl)benzoic acid
SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O
InChIKey: RMWVZGDJPAKBDE-UHFFFAOYSA-N
XLogP: 2.1
Polar surface area: 63.6 Å²
H-bond donors: 1
H-bond acceptors: 7
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Phase 3
Molecule type: Small molecule
Indications: Recurrent thrombophlebitis, insulin resistance

via ChEMBL · EBI

Research

206 papers

Triflusal.Drugs · 1998
Photosensitivity to Triflusal.The journal of allergy and clinical immunology. In practice · 2021
Triflusal for preventing serious vascular events in people at high risk.The Cochrane database of systematic reviews · 2005
Triflusal: an antiplatelet drug with a neuroprotective effect?Cardiovascular drug reviews · 2006
Triflusal in Patients with Acute Coronary Syndrome and Acetylsalicylic Acid Hypersensitivity.Cardiology · 2021

via PubMed

Wikidata facts

Subclass of: chemical compound
Mass: 248.03
Has use: medication

Show 5 more facts

chemical formula: C₁₀H₇F₃O₄
canonical SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O
defined daily dose: 0.6
subject has role: platelet aggregation inhibitors
Commons category: Triflusal

Sources (3)

via Wikidata · CC0

~3 min read

Encyclopedic overview

5 sections

Contents

Mechanism of action
Indication
Prevention of stroke
Pharmacokinetics
References

Triflusal has multiple mechanisms of action that contribute to the effect of the drug. It is a COX-1 inhibitor. It also inhibits the activation of nuclear factor k-B, which in turn regulates the expression of the mRNA of the vascular cell adhesion molecule-1 needed for platelet aggregation. Additionally, Triflusal preserves vascular prostacyclin which yields an anti-platelet effect. Triflusal also blocks phosphodiesterase, increasing cAMP concentration as well as can increase nitric oxide synthesis in neutrophils.

Excerpted from Wikipedia’s “triflusal” article, available under the CC BY-SA 4.0 licence.